title: Rolipram, a phosphodiesterase 4 inhibitor, stimulates inducible cAMP early repressor expression in osteoblasts.
abstract: Phosphodiesterase (PDE) 4 inhibitors have been shown to induce the cAMP-mediated signaling pathway by inhibiting cAMP hydrolysis. This study investigated the effect of a PDE4 inhibitor on the expression of the inducible cAMP early repressor (ICER), which is an endogenous inhibitor of CRE- mediated transcription, in osteoblastic cells. RT-PCR analysis revealed that rolipram, a PDE4 inhibitor, stimulates the ICER mRNA in a dose dependent manner. The induction of ICER mRNA expression by rolipram was suppressed by the inhibitors of protein kinase A (PKA) and p38 MAPK, suggesting the involvement of PKA and p38 MAPK activation in ICER expression by rolipram. It was previously shown that rolipram induced the expression of TNF-related activation-induced cytokine (TRANCE, also known as RANKL, ODF, or OPGL) in osteoblasts. This paper provides evidences that a transcriptional repressor like ICER might modulate TRANCE mRNA expression by rolipram in osteoblasts.
authors.affiliation: College of Pharmacy, Sookmyung Women's University, Seoul 140-742, Korea.
authors.forename: Eun Sook
authors.initials: ES
authors.lastname: Cho
authors.forename: Ja Heon
authors.initials: JH
authors.lastname: Yu
authors.forename: Mi Sun
authors.initials: MS
authors.lastname: Kim
authors.forename: Mijung
authors.initials: M
authors.lastname: Yim
mesh_terms: D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors*; D000818:Animals; D021461:Animals, Outbred Strains; D051786:Cyclic AMP Response Element Modulator; D017868:Cyclic AMP-Dependent Protein Kinases / Q000378:metabolism; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4; D004268:DNA-Binding Proteins / Q000235:genetics / Q000378:metabolism*; D015870:Gene Expression / Q000187:drug effects; D051379:Mice; D010006:Osteoblasts / Q000187:drug effects* / Q000378:metabolism; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology*; D020889:Rolipram / Q000494:pharmacology*; D014157:Transcription Factors / Q000235:genetics / Q000378:metabolism*; D048051:p38 Mitogen-Activated Protein Kinases / Q000378:metabolism
chemical_list: D004268:DNA-Binding Proteins; D010726:Phosphodiesterase Inhibitors; D014157:Transcription Factors; D051786:Cyclic AMP Response Element Modulator; D017868:Cyclic AMP-Dependent Protein Kinases; D048051:p38 Mitogen-Activated Protein Kinases; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4; D020889:Rolipram
references.citation: Bone. 1997 Oct;21(4):297-304
references.pmid: 9315332
references.citation: J Biol Chem. 1997 Oct 3;272(40):25190-4
references.pmid: 9312132
references.citation: Oncogene. 1997 Nov 13;15(20):2493-500
references.pmid: 9395245
references.citation: Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3597-602
references.pmid: 9520411
references.citation: Cell. 1998 Apr 17;93(2):165-76
references.pmid: 9568710
references.citation: J Bone Miner Res. 1998 Dec;13(12):1846-51
references.pmid: 9844102
references.citation: Yonsei Med J. 1999 Apr;40(2):166-72
references.pmid: 10333721
references.citation: Jpn J Pharmacol. 1999 Apr;79(4):477-83
references.pmid: 10361888
references.citation: Drugs Aging. 1999 Aug;15(2):117-29
references.pmid: 10495071
references.citation: Arch Pharm Res. 2004 Dec;27(12):1258-62
references.pmid: 15646801
references.citation: Front Neuroendocrinol. 2000 Apr;21(2):103-32
references.pmid: 10764527
references.citation: Bone. 2000 Dec;27(6):811-7
references.pmid: 11113392
references.citation: J Allergy Clin Immunol. 2001 Nov;108(5):671-80
references.pmid: 11692087
references.citation: Bone. 2002 Jul;31(1):252-9
references.pmid: 12110442
references.citation: J Bone Miner Res. 2002 Sep;17(9):1667-79
references.pmid: 12211438
references.citation: J Biol Chem. 2002 Dec 13;277(50):48868-75
references.pmid: 12364326
references.citation: Bone. 2003 May;32(5):483-90
references.pmid: 12753864
references.citation: Mol Endocrinol. 1992 Nov;6(11):1834-42
references.pmid: 1480173
references.citation: Mol Endocrinol. 1992 Dec;6(12):2153-9
references.pmid: 1337147
references.citation: Mol Endocrinol. 1993 Mar;7(3):399-408
references.pmid: 8483479
references.citation: Nature. 1993 Sep 23;365(6444):314-20
references.pmid: 8397338
references.citation: Cell. 1993 Dec 3;75(5):875-86
references.pmid: 8252624
references.citation: J Bone Miner Res. 1993 Oct;8(10):1163-71
references.pmid: 8256653
references.citation: Proc Natl Acad Sci U S A. 1995 Oct 10;92(21):9633-7
references.pmid: 7568187
references.citation: Prostaglandins. 1995 Jun;49(6):383-95
references.pmid: 7480806
references.citation: J Bone Miner Res. 1996 Jan;11(1):62-71
references.pmid: 8770698
references.citation: J Biol Chem. 1996 Oct 11;271(41):25375-81
references.pmid: 8810303
references.citation: Endocrinology. 1997 Sep;138(9):3594-600
references.pmid: 9275040
references.citation: Mol Endocrinol. 1997 Sep;11(10):1415-24
references.pmid: 9280057
references.citation: Biochem Pharmacol. 1997 Sep 1;54(5):613-7
references.pmid: 9337078